Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Pursuant to Regulation 30 of the SEBI [Listing Obligations and Disclosure Requirements] Regulations, 2015, we hereby inform that the Company has planned investor interaction through a teleconference call at 4:00 p.m. on Friday, May 28, 2018 for post results Q&A; session. Zydus Cadila gets USFDA nod for Carbidopa tablets
Zydus Cadila has received final approval from the US health regulator to market Carbidopa tablets, used for treating Parkinson's symptoms which incl Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus receives final approval from the USFDA for Carbidopa Tablets
Zydus Cadila gets USFDA nod for anesthesia drug
Zydus Cadila said it has received an approval from the USFDA to market Succinylcholine Chloride injection, used as part of general anesthesia procedure, in the American market Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus receives final approval for Succinylcholine Chloride Injection USP and tentative approval for Plerixafor Injection from the USFDA Board to consider FY18 results & Dividend on May 25, 2018
Cadila Healthcare Ltd has informed BSE that the meeting of the Board of Directors of the Company will be held on May 25, 2018, inter alia, to approve the audited financial results for the quarter / year ended on March 31, 2018 and to recommend dividend for the financial year ended on March 31, 2018. Further, as per code of conduct for prevention of Insider Trading adopted by the Company under SEBI [Prohibition of Insider Trading] Regulations,... Board Meeting Is Scheduled To Be Held On May 25, 2018.
We hereby inform that the meeting of the Board of Directors of the Company will be held on Friday, May 25, 2018 to consider apart from other agenda items to approve the audited financial results for the quarter / year ended on March 31, 2018 and to recommend dividend for the financial year ended on March 31, 2018. Further, as per code of conduct for prevention of Insider Trading adopted by the Company under SEBI [Prohibition of Insider Trading]... Announcement under Regulation 30 (LODR)-Diversification / Disinvestment
Further to our letter dated April 27, 2018 informing the Stock Exchange about the execution of agreement for sale of shares to Bayer (South East Asia) Pte. Limited, we hereby inform that the Company has received the Exit Price for such sale of shares in terms of the Joint Venture Agreement. Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus received final approval from the USFDA for Bumetanide Tablets USP Announcement under Regulation 30 (LODR)-Diversification / Disinvestment
Cadila Healthcare Limited ('the Company') had entered into Joint Venture Agreement ['JVA'] with Bayer (South East Asia) Pte. Limited ('Bayer') on January 28, 2011. Both Bayer and the Company hold 2.50 crore Equity Shares of Rs. 10/- each fully paid-up of Bayer Zydus Pharma Private Limited ('Joint Venture Company'). As per the terms of the JVA, the Company is selling 1,25,00,001 Equity Shares at a value determined in terms of JVA to Bayer...